(Q33809452)

29 July 2017

1 reference

title

Clinical implications of hepatitis C viral kinetics (English)

1 reference

29 July 2017

1 reference

Zeuzem S

1

1 reference

29 July 2017

publication date

1 January 1999

1 reference

29 July 2017

published in

Journal of Hepatology

1 reference

29 July 2017

volume

31 Suppl 1

1 reference

29 July 2017

page(s)

61-64

1 reference

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Dynamics of hepatitis C viremia following interferon-alpha administration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Hepatitis C: viral kinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980376-6

7 January 2021

10.1016/S0168-8278(99)80376-6

Identifiers

DOI

1 reference

29 July 2017

1 reference